Deep Apple Therapeutics CEO Spiros Liras (L) and interim CSO Paul Da Silva Jardine
December 14, 2023 07:30 AM EST
Financing
Startups
AI

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Kyle LaHucik

Senior Reporter

Two for­mer chem­istry VPs who worked at Pfiz­er’s car­dio­vas­cu­lar and meta­bol­ic re­search group have come to­geth­er to build a new biotech as the obe­si­ty drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times